补肾解毒汤联合复方α-酮酸治疗慢性肾衰竭继发性甲状旁腺功能亢进症疗效观察

Observation of Efficacy of Bushenjiedutang Combined Compound α-Ketoacid Tablets in Treating Secondary Hyperparathyroidism of Patients with Chronic Renal Failure

目的观察补肾解毒汤联合复方α-酮酸治疗慢性肾衰竭(CRF)继发性甲状旁腺功能亢进症(SHPT)患者的效果。方法将93例慢性肾衰竭SHPT未开始血液透析患者随机分为两组。两组均予复方α-酮酸和常规治疗,治疗组加用补肾解毒汤治疗。观察临床症状、体征积分和肾功能、全段血清甲状旁腺素(iPTH)、碱性磷酸酶(ALP)、钙、磷、血红蛋白(HGB)指标改善情况。结果两组治疗后iPTH、ALP、SCr、BUN、磷均较治疗前有不同程度下降,临床症状、体征积分及钙、HGB均有不同程度的改善(P<0.05或P<0.01),治疗组临床症状积分及iPTH、ALP、Scr、BUN、磷、HGB较对照组改善更显著(P<0.05)。结论补肾解毒汤联合复方α-酮酸治疗是治疗CRF合并SHPT的有效方法。

Objective To observe the efficacy of Bushenjiedutang combined compound α-keto acid in treating secondary hyperparathyroidism（SHPT） of patients with chronic renal failure（CRF）.Methods Totally 93 cases secondary hyperparathyroidism of patients with chronic renal failure who were not on dialysis therapy were randomized into two groups.Both of the two groups were treated as conventional therapies and were given compound α-ketoacid tablets,in addition,and the treatmentgroup were given Bushenjiedutang,to observe the change of clinical integral in symptom and signs,serum phosphorus,calcium,intact parathyroid hormone（iPTH）,alkaline phosphatase（ALP）,renal function,haemoglobin.Results Compared with pretherapy,the iPTH,ALP,serum phosphorus,Scr and BUN of all two group were lower,and all clinical integral in symptom and signs,serum calcium,haemoglobin were improved significantly（P0.05或P0.01）,and clinical integral in symptom and signs,Scr,BUN,iPTH,ALP,serum phosphorus and haemoglobin were improved more significantly in the treatment group than in the control group（P0.05）.Conclusion Bushenjiedutang combined compound α-ketoacid is an effective method in treating Secondary Hyperparathyroidism of Patients with Chronic Renal Failure.